Fibronectin is a serum biomarker for Duchenne muscular dystrophy
about
Hanging on for the ride: adhesion to the extracellular matrix mediates cellular responses in skeletal muscle morphogenesis and diseaseSolid-phase extraction strategies to surmount body fluid sample complexity in high-throughput mass spectrometry-based proteomicsProteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy.Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophiesDiscovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy.Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.Laminin and Matrix metalloproteinase 11 regulate Fibronectin levels in the zebrafish myotendinous junctionConcurrent Label-Free Mass Spectrometric Analysis of Dystrophin Isoform Dp427 and the Myofibrosis Marker Collagen in Crude Extracts from mdx-4cv Skeletal Muscles.Circulating Biomarkers for Duchenne Muscular Dystrophy.Chaperoning heat shock proteins: proteomic analysis and relevance for normal and dystrophin-deficient muscle.Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy.Pathoproteomic profiling of the skeletal muscle matrisome in dystrophinopathy associated myofibrosis.Mass spectrometry-based protein analysis to unravel the tissue pathophysiology in Duchenne muscular dystrophy.Progressive muscle proteome changes in a clinically relevant pig model of Duchenne muscular dystrophy.Understanding the molecular consequences of inherited muscular dystrophies: advancements through proteomic experimentation.Liquid-phase based separation systems for depletion, prefractionation, and enrichment of proteins in biological fluids and matrices for in-depth proteomics analysis-An update covering the period 2014-2016.Label-free mass spectrometric analysis of the mdx-4cv diaphragm identifies the matricellular protein periostin as a potential factor involved in dystrophinopathy-related fibrosis.Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients.Non-Invasive Biomarkers for Duchenne Muscular Dystrophy and Carrier Detection.N-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy.Neo-epitope Peptides as Biomarkers of Disease Progression for Muscular Dystrophies and Other Myopathies.Mapping the human skeletal muscle proteome: progress and potential.Expression of CTGF/CCN2 in response to LPA is stimulated by fibrotic extracellular matrix via the integrin/FAK axis.Cross-sectional serum metabolomic study of multiple forms of muscular dystrophy.Evaluation of fibronectin 1 in one dried blood spot and in urine after rhGH treatment.Non-Glycanated Biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne Muscular Dystrophy therapeutics.Mapping QTL for white striping in relation to breast muscle yield and meat quality traits in broiler chickens.[Molecular pathogenesis of Duchenne muscular dystrophy-related fibrosis].Novel proteomic biomarkers for skeletal muscle diseases.Combined use of protein biomarkers and network analysis unveils deregulated regulatory circuits in Duchenne muscular dystrophy.Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies
P2860
Q28087402-B879655D-9BDE-4AFB-9921-4871B0F13A30Q28650185-9C67445C-257F-4250-ADCD-C415EC619BDBQ33675040-350F1D9F-B39B-42D9-962D-1FA683DACF33Q33991470-E8FDABA0-2B39-4E5A-B81A-4BEB68DA6525Q34555477-C67B18A7-706C-4EE5-8BA1-B0F7C51DECF3Q35991086-A1BF8ED7-B987-4BCC-9922-E16C0C5E4C03Q36069707-343EA086-A357-4C23-B73B-2D730AEBBD59Q36305436-B900F364-BC8F-49B9-8A5E-8151AC27AB6CQ36855772-AA6BFF98-3B72-4AC1-8852-EA9AC58D167EQ37566483-D1C8803E-F748-41F2-B5DC-A265EEDF4E7EQ37610530-4E701AD5-8D9E-4443-BDC0-23736B37E2A2Q38217473-FFBDF7CA-0D70-4241-B5D1-632A7A12CAF0Q38302852-FFA2CE69-9FC1-4067-B869-4108024C743CQ38563300-41637478-688F-49BC-85E3-C7F880048F50Q38717697-0451223C-686C-4EE2-AC73-A9E238695A47Q38820669-1569AAF3-13FE-49B8-AAF0-E1046740AE5AQ38850056-AC2815EA-AC3C-4252-ADD2-F174846B6F18Q38978587-314C1C8F-C3D1-4F42-9D53-7C23550C9076Q39033229-D94BA05A-FD5C-4EF4-9F8F-1AB9990A8817Q40198410-CF696A27-729E-42F0-8C2B-09EB48ACDEFBQ40820281-9AF3FF89-2B71-4016-BA65-E0543DB239CEQ41228417-34D32D16-FBA6-4BA0-8336-A2BB2EE7D029Q42363358-EE444396-C5FD-47B4-860D-807EFFDD840FQ47986644-F43DD25D-B776-4931-854C-E7BA76260D5FQ49918232-5227EB6C-9F3A-478F-AB04-9E0CC7313A42Q50019659-89BB8F56-01AB-45AB-81A0-A14D6FC115CBQ51417278-CF3EDC49-5F7B-4AC2-9ED2-399836C428B0Q52372774-81BA7848-D3AC-4A5C-A362-464605416E2EQ52648408-3AA692E4-B12D-47CA-9751-3A9FF2E98C16Q52925630-0DBD247B-1685-4157-9E45-12E4CE19588EQ53216634-843AC4A3-0423-4C03-BCDA-D416FDD0C25CQ54965928-50B0A48B-C46D-4B44-8799-73274269AD5BQ57831005-79C7775B-881C-401E-B6AE-39E3538F62EF
P2860
Fibronectin is a serum biomarker for Duchenne muscular dystrophy
description
im März 2014 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2014
@uk
name
Fibronectin is a serum biomarker for Duchenne muscular dystrophy
@en
Fibronectin is a serum biomarker for Duchenne muscular dystrophy
@nl
type
label
Fibronectin is a serum biomarker for Duchenne muscular dystrophy
@en
Fibronectin is a serum biomarker for Duchenne muscular dystrophy
@nl
prefLabel
Fibronectin is a serum biomarker for Duchenne muscular dystrophy
@en
Fibronectin is a serum biomarker for Duchenne muscular dystrophy
@nl
P2093
P2860
P50
P356
P1476
Fibronectin is a serum biomarker for Duchenne muscular dystrophy
@en
P2093
Amina Chaouch
André M. Deelder
F. Cynthia Martin
Hans Dalebout
Michela Guglieri
Monika Hiller
Stijn Oonk
P2860
P304
P356
10.1002/PRCA.201300072
P50
P577
2014-03-11T00:00:00Z